Tyr723
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Phosphorylation Site Page:
Tyr723 - Kit (mouse)

Site Information
SCDSSNEyMDMKPGV    SwissProt Entrez-Gene
Predicted information: Scansite
Orthologous residues: Kit (human): Y721, Kit (rat): Y722
Blast this site against: NCBI  SwissProt  PDB 
Available spectra:  2 CST

In vivo Characterization
Methods used to characterize site in vivo: [32P] bio-synthetic labeling (15), flow cytometry (14), immunoprecipitation (14), mass spectrometry (2, 4, 5, 8, 9, 10, 11), mutation of modification site (7, 13, 14, 15), phospho-antibody (6, 12, 13, 14, 15), western blotting (6, 12, 14)
Disease tissue studied: testicular cancer (2, 4)
Relevant cell line - cell type - tissue: 32D (myeloid) (14), BaF3 ('B lymphocyte, precursor') (7, 13), COS (fibroblast) (15), F9 (testicular) (2), IC2 (mast) (12), mast-bone marrow (7), mast-bone marrow [PTPRA (mouse), homozygous knockout] (6), P19 (testicular) (4), PYS-2 (epithelial) (5)

Controlled by
Treatments: bortezomib (1), SCF (6, 7, 12, 13, 15), SU6656 (6)

Downstream Regulation
Effects of modification on Kit: molecular association, regulation (13, 14, 15), phosphorylation (7)
Effects of modification on biological processes: cell cycle regulation (7, 13, 14)
Induce interaction with: PIK3R1 (mouse) (13, 14, 15)


References

1

Liu S, et al. (2010) Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell 17, 333-47
20385359   Curated Info

2

(2010) CST Curation Set: 9105; Year: 2010; Biosample/Treatment: cell line, F9/untreated; Disease: testicular cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-102) Cat#: 9416
Curated Info

3

(2010) CST Curation Set: 9104; Year: 2010; Biosample/Treatment: cell line, ES J1/untreated; Disease: -; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-102) Cat#: 9416
Curated Info

4

(2010) CST Curation Set: 9109; Year: 2010; Biosample/Treatment: cell line, P19/untreated; Disease: testicular cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-102) Cat#: 9416
Curated Info

5

(2010) CST Curation Set: 9108; Year: 2010; Biosample/Treatment: cell line, PY2/untreated; Disease: -; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-102) Cat#: 9416
Curated Info

6

Samayawardhena LA, Pallen CJ (2008) Protein-tyrosine phosphatase alpha regulates stem cell factor-dependent c-Kit activation and migration of mast cells. J Biol Chem 283, 29175-85
18725415   Curated Info

7

Yu M, et al. (2006) The scaffolding adapter Gab2, via Shp-2, regulates kit-evoked mast cell proliferation by activating the Rac/JNK pathway. J Biol Chem 281, 28615-26
16873377   Curated Info

8

(2006) CST Curation Set: 1516; Year: 2006; Biosample/Treatment: cell line, Thom/serum starved; Disease: -; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

9

(2006) CST Curation Set: 1517; Year: 2006; Biosample/Treatment: cell line, Thom/serum starved; Disease: -; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

10

(2006) CST Curation Set: 1518; Year: 2006; Biosample/Treatment: cell line, Thom/untreated; Disease: -; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

11

(2006) CST Curation Set: 1519; Year: 2006; Biosample/Treatment: cell line, Thom/untreated; Disease: -; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

12

Shivakrupa R, Bernstein A, Watring N, Linnekin D (2003) Phosphatidylinositol 3'-kinase is required for growth of mast cells expressing the kit catalytic domain mutant. Cancer Res 63, 4412-9
12907613   Curated Info

13

Hashimoto K, et al. (2003) Necessity of tyrosine 719 and phosphatidylinositol 3'-kinase-mediated signal pathway in constitutive activation and oncogenic potential of c-kit receptor tyrosine kinase with the Asp814Val mutation. Blood 101, 1094-102
12393643   Curated Info

14

Gommerman JL, et al. (2000) Differential stimulation of c-Kit mutants by membrane-bound and soluble Steel Factor correlates with leukemic potential. Blood 96, 3734-42
11090054   Curated Info

15

Serve H, Hsu YC, Besmer P (1994) Tyrosine residue 719 of the c-kit receptor is essential for binding of the P85 subunit of phosphatidylinositol (PI) 3-kinase and for c-kit-associated PI 3-kinase activity in COS-1 cells. J Biol Chem 269, 6026-30
7509796   Curated Info

Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.